Biosimilars: The Next Frontier

The launch of biosimilars in the U.S. introduces competition to a trending specialty drug marketplace. Biosimilars are approved by the FDA for safety and are certified for “having no meaningful clinical difference” from their reference drugs. The nature of biologics makes it impossible to manufacture exact duplicates, as is done with generics. With savings estimated at $54 billion over 10 years, we must address the market failures that are inhibiting adoption. 

PBGH and the Integrated Benefits Institute (IBI) held this two-day webinar event on August 12 and 13.  The event brochure and presentations are available online here.   

Wednesday, August 12, 2020

Biosimilars; The Big Picture, the Opportunity, the Pipeline 

Kelly McDevitt, Integrated Benefits Institute (Moderator)
Juliana Reed, MS, Pfizer
Wayne Winegarden, PhD, Center for Medical Economics and Innovation 

Biosimilars and Cancer
Lucy Langer MD, The US Oncology Network 

Benefits Design Strategies to Optimize Access and Affordability
Anne Ladd, PBGH (Moderator)
Melissa Mantong, PharmD, MS, FCSHP, CalPERS
Ladd Carman, BPharm, Costco
Bill Dinger, MBA, CPA, The Walt Disney Company 

Thursday, August 13, 2020 

Provider Strategies to Manage Total Cost of Care
Lauren Vela, PBGH (Moderator)
Kimberly Tsai, PharmD, CGS, MemorialCare Medical Foundation
Megan McIntyre, PharmD, MHA, Virginia Mason Medical Center  

Case Study in Value-Based Care
Sameer Awsare, MD,The Permanente Medical Group 

Quantifying the Biosimilar Opportunity and Making Data-Driven Decisions
Heather Sundar, PharmD, Archimedes, Inc.
PBGH did not record this presentation at the request of Archimedes, Inc. 

Impacting Workplace Productivity by Optimizing Affordability and Access
Anne Ladd, PBGH (Moderator) 
Brian Gifford, PhD, Integrated Benefits Institute
Rob Paczkowski, CEBS, eBay